TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01675349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prick test Chenopodium album allergen extract
Description: This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
Study: NCT04881279

Intervention type: OTHER
Intervention: Event
Description: Ransomware attack
Study: NCT03648528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00460902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Study: NCT00975676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography / tandem mass spectometry
Description: Determination of estrogen levels through gas chromatography.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography / tandem mass spectometry
Description: Determination of estrogen levels through gas chromatography.
Study: NCT02538315

Intervention type: DRUG
Intervention: [18F]FDOPA PET/CT
Description: Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
Study: NCT02548078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administered intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administered intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
Description: A single dose administered intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
Description: A single dose administered intramuscular
Study: NCT02242643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval™ Quadrivalent
Description: 1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® Quadrivalent
Description: 1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
Study: NCT00611169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban
Description: tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
Study: NCT00372853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 administered at a dose of 37.5mg/day every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
Study: NCT03210649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519
Description: Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519
Description: Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
Study: NCT03228147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04058002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
Description: 17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
Description: 17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
Study: NCT02125071

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
Study: NCT03876106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014
Description: Topical
Study: NCT00869947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered ankle-foot prosthesis
Description: The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No device
Study: NCT01210651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga Practice Group
Description: The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Education Group
Description: The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
Study: NCT00895726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD209
Description: Oral tablets twice per day for 56 days
Study: NCT01498315

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination following hysterectomy
Study: NCT01690468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine
Description: Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
Study: NCT02437357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Training
Description: 8 group sessions á 60 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positivity Training
Description: 8 group sessions á 60 min
Study: NCT04058834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434
Description: Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0385-0434)
Description: Healthy volunteers will receive one injection s.c.
Study: NCT02478645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron 0.3
Description: The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron 0.45
Description: The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron 0.6
Description: The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
Study: NCT02469883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinotecean
Study: NCT02397447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momordica charantia
Description: Momordica Charantia: 2000 mg per day for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2000 mg per day for three months
Study: NCT04099485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Best Practice Advisory
Description: The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
Study: NCT00698347

Intervention type: DEVICE
Intervention: M2a-Magnum™ Hip System
Study: NCT00616824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermamatrix to cover lateral aspect of tissue expander
Description: Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior to cover lateral aspect of tissue expander
Description: Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
Study: NCT04360785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
Study: NCT01144390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone maintenance treatment
Description: methadone maintenance treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone maintenance treatment
Description: methadone maintenance treatment
Study: NCT03755973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFA
Description: Long-acting exogenous ovarian stimulation
Study: NCT02840227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with opioid analgesia
Description: General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia
Description: Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
Study: NCT04519762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycophos (Sodium Glycerophosphate)
Description: Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotics
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Inotropes
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotropes
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study: NCT03092791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Description: sIPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Description: sIPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Description: sIPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Description: sIPV intramuscular injection
Study: NCT03755973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFA
Description: Long-acting exogenous ovarian stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: Daily rFSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: Daily rFSH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: Daily rFSH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed daily rFSH dosing protocol of 200-300 IU
Description: The dose of daily rFSH is fixed at 200 or 300 IU

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed daily rFSH dosing protocol of 200-300 IU
Description: The dose of daily rFSH is fixed at 200 or 300 IU

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Step-down daily rFSH dose
Description: The dose of daily rFSH is progressively reduced
Study: NCT04287283

Intervention type: OTHER
Intervention: Hyperbaric Oxygen
Description: 40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
Study: NCT02825251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected s.c. /subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c. /subcutaneously (under the skin)
Study: NCT02080403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Chlorhexidine gluconate chip
Description: Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
Study: NCT02089139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discogel
Description: DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks
Study: NCT02987647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hidrafemme
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vagidrat
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lubrinat
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antrofi
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
Study: NCT02812992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Study: NCT03795168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial vibrating system
Description: The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial vibrating system
Description: The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial vibrating system sham
Description: A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
Study: NCT02861196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy, Radical cystectomy
Description: Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
Study: NCT04361383

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: the patient will receive general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block type 3
Description: patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.